Pilot Study of Liver Fibrosis Stage Assessment by Tep Fibroblast Activation Protein Imaging (68Ga-FAPI-46 TEP/TDM) in Patients With Biopsy for Suspected or Proven Nonalcoholic Steatohepatitis (NASH) is a PHASE2 clinical asset sponsored by Central Hospital, Nancy, France in Non-alcoholic Steatohepatitis. SEO and diligence focus: PET scan of 68Ga-FAPI, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.